Author: Bill Ross | Published: May 29, 2026 | Updated: May 29, 2026 Medical device marketing is moving through its largest channel shift in a decade. The global market will cross $800 billion by 2028, FDA AI clearances are doubling every two years, and healthcare and pharma digital ad spend now outpaces traditional advertising five to one. For marketing leaders inside medtech, the question is no longer whether to go digital. The question is how to allocate a budget across search, social, content, field, and emerging AI channels when buyer behavior is changing faster than most planning cycles can keep up. This article walks through seven trends shaping medical device marketing through 2028, with the data and projections behind each. Key Takeaways The global medical device market is on track to grow from $679 billion in 2025 to $807 billion by 2028, an addition of roughly $128 billion in three years. Most of that expansion is structural, not cyclical. Chronic illness now drives 74% of global deaths, and the population aged 60 and older will rise 40% between 2020 and 2030. These are inelastic demand drivers, meaning device manufacturers can rely on the underlying tailwind even when individual product categories cool off. What this means for marketing teams is that category-level demand is no longer the constraint. Share of voice is. As the market expands, more entrants enter each subcategory, more competitors invest in content and search, and the cost to capture an HCP’s attention rises. Companies that treated marketing as a cost center during the lean years now find themselves outranked by competitors who built editorial authority during the same period. The practical implication is an adjustment to the planning horizon. If the category compounds at 5.9% and your marketing budget grows at the same rate, you are losing share. Outpacing the category means committing to a multi-year investment in content strategy, paid search, and editorial publishing well before competitors do, because the lag from investment to compounded organic traffic is measured in quarters, not months.
The medical device buyer reads white papers before they ever speak to a rep. Marketing’s job is to be the source of those white papers, not the interruption after they are already read. – Emulent Strategy Team
US healthcare and pharma digital ad spending reached $24.8 billion in 2025, up more than 13% year over year, while traditional ad spending shrank to roughly $7.9 billion. Our projection through 2028 puts digital at $30.4 billion against $5.6 billion for traditional, a 5.4x ratio. The 2025 inflection point is also worth flagging: it was the first year that social media ad spend in healthcare and pharma combined surpassed linear TV. For medical device companies that have historically underweighted digital relative to pharma, this widens an already significant gap. Pharma accounts for roughly 88% of healthcare digital ad dollars, leaving devices and providers fighting for the remaining 12%. The implication is not that device companies need to spend like pharma. It is that the cost of being absent from digital channels is rising every year as buyer attention concentrates there. What to do with this shift in 2026 planning The FDA cleared 295 AI and machine learning enabled medical devices in 2025, a record year. Cumulative clearances reached 1,451 by year end, up from 692 in 2023. We project the cumulative total will pass 2,700 by 2028 if the new-clearance rate moderates into a 350 to 425 per year band as Predetermined Change Control Plans streamline iterative approvals. Three implications for marketing flow from this data. First, product differentiation gets harder, because radiology still dominates with roughly 76% of cleared devices, meaning crowded segments require sharper positioning. Second, claim governance becomes a competitive moat: companies that publish FDA-cleared performance data faster than competitors win in HCP search. Third, the median 142-day clearance timeline means product marketing teams should pre-build content assets during submission, not after clearance, since waiting costs a quarter of category-leading SEO opportunity. This is also where AI SEO and generative engine optimization start to matter. When a surgeon searches for “FDA-cleared AI software for chest X-ray triage” in ChatGPT or Perplexity, the answer is synthesized from authoritative third-party content. If your product page is the only place that information lives, you are invisible to the buyer. Companies winning this layer publish on industry sites, contribute to peer-reviewed journals, and structure their own content for AI ingestion. The US remote patient monitoring market grew from $14.15 billion in 2024 to $16.09 billion in 2025 and is projected to reach $29.13 billion by 2030. CAGR sits at 12.6%, with the patient segment growing faster than the hospital segment. This is a structural change in the medtech buyer set, because for the first time in a major device category, the end user buys the product as well as uses it. What this rewrites for marketing is the channel mix for any device that touches RPM, continuous glucose monitoring, cardiac monitoring, or sleep diagnostics. The HCP funnel is no longer the only funnel. Brand videography, patient education content, and review-platform reputation now matter as much as journal placements. Reimbursement at $110 to $150 per patient per month sustains provider economics, which means physicians have a financial reason to recommend devices to patients, and patients arrive at the conversation pre-researched. Companies that succeed in this transition treat their consumer marketing as a layered system: clinical credibility content for the HCP recommendation, accessible explainers for the patient, and reimbursement guidance for the practice manager. The risk of treating this as a single audience is significant, because medical claims that resonate with a cardiologist confuse the patient, and patient-friendly language can violate FDA promotional rules. HCP channel preferences moved further between 2019 and 2025 than in the previous two decades combined. Face-to-face rep visits dropped from 65% of preferred interactions in 2019 to 28% in 2025. Digital channels (email, portals, webinars, social) climbed from 20% to 44%. Hybrid (remote video calls) settled at 28%. Our projection through 2028 puts digital at 50%, hybrid at 29%, and face-to-face at 21%. Rogers diffusion theory predicts what happens next. Adoption decelerates after the 50% mark, which means the digital share will not keep climbing at 2020-2025 rates. Face-to-face will hold a 20% floor, supported by procedural specialties, KOL meetings, and high-value capital equipment deals where committee dynamics require in-person presence. The companies in trouble are the ones that cut field budgets too aggressively in 2024 and 2025 and now face stalled 7-figure pipeline.
Treating digital as a cheaper version of field reps is what kills omnichannel programs. The two channels carry different jobs in the funnel, and trying to make digital sell what reps used to sell wastes the budget. – Emulent Strategy Team
A preference-reality gap also matters: 84% of HCPs prefer increased or maintained virtual interactions, but in the top European markets, only about half of actual outreach matches those preferences. Closing that gap is a near-term win for any device company willing to invest in HCP portal content, on-demand webinars, and asynchronous video communication. The underlying healthcare buyer behavior is also covered in our healthcare marketing trends report. We project the medtech digital marketing budget will reallocate substantially through 2028. Field sales and in-person activity drops from 22% of total spend to 14%. Search and SEO rises from 16% to 21%. LinkedIn and social grows from 14% to 19%. Content and webinars expands from 15% to 18%. Print, trade press, and physical events drops from 13% to 6%. Email and display hold roughly flat. The growth in search reflects two compounding forces. The first is the rise of Google AI Overviews and generative search, which require structured, citable content that ranks across both classic SERPs and AI-generated answers. The second is procurement behavior: 84% of physicians say they ignore standardized marketing materials, but the same physicians turn to search engines when they need decision-support information for a specific clinical scenario. Where the reallocated dollars work hardest The companies that will struggle are those that cut field spend faster than they built the digital capacity to replace it. Field still anchors Tier 3 and Tier 4 deals, which connects directly to the question of cost per qualified lead. Healthcare lead costs range widely. Our 2025 benchmarks put Tier 1 consumables at $210 average CPL, Tier 2 diagnostic devices at $375, Tier 3 capital equipment at $595, and Tier 4 AI software-as-medical-device and enterprise platforms at $830. We project all four tiers will rise 17 to 23% by 2028 as LinkedIn CPM inflation, longer buying committees, and AI Overview zero-click search compress organic funnels.
A surgical robot lead and a consumables lead share a sales platform but nothing else. Spending the same per-lead on both is the most common mistake we see in medtech budgets. – Emulent Strategy Team
The most reliable lever for reducing CPL at Tier 3 and Tier 4 is specialty-specific content. Generic clinical messaging gets ignored by 84% of physicians, so the cost of producing it is essentially wasted. Building a peer-reviewed-quality content library for one subspecialty, then expanding to adjacent specialties as the program proves out, reduces CPL by 25 to 35% in our client benchmarks. The unit economics also explain why patient capital exists for medtech editorial programs that take 6 to 12 months to reach positive ROI: the compounded lifetime value of a Tier 3 lead easily justifies the front-loaded investment.
Compliance is not a marketing limitation. It is a credibility moat. Companies that publish cleared, evidenced claims build authority that uncleared competitors cannot copy. – Emulent Strategy Team
Companies treating CPL as a single metric across product lines also miss the funnel-stage mix. A $210 catheter lead is typically late-stage. A $830 AI platform lead is typically early-stage research. Comparing them without that context produces budget decisions that punish the wrong programs. The data in this report points to a single conclusion. The medical device companies that win between now and 2028 are the ones that treat marketing as a multi-year investment in editorial authority, channel diversification, and specialty-specific content rather than as a campaign-by-campaign expense. Our team works with medtech brands on the full stack required to do this well: medical device marketing strategy, Search Everywhere Optimization for AI-driven search visibility, regulated-content production, and HCP-targeted programs across LinkedIn, paid search, and earned editorial. If your team is planning the 2026 budget and weighing how to reallocate field, content, and digital ad dollars, we would be glad to walk through the trade-offs with you. Schedule a free marketing strategy call with our team to discuss how we can help your medical device marketing program perform through this transition.
Medical Device Marketing Trends and 2026-2028 Projections
What does the $800 billion medical device market mean for marketing strategy?
Why is digital ad spend outpacing traditional channels by such a wide margin?
How does FDA AI clearance growth reshape product launch marketing?
What does the remote patient monitoring boom mean for D2C marketing?
How have HCP channel preferences shifted, and where will they settle?
Where should medical device marketers move their budgets by 2028?
What should you budget per qualified lead by device complexity?
How Emulent helps medical device companies grow
